Meta‐analysis of Alzheimer’s disease clinical trial time savings results
Suzanne B. Hendrix, Kent Hendrix, Benjamin A Haaland, Patrick P O'Keefe, Newman Knowlton, Craig Mallinckrodt, Samuel P. Dickson · 2025
Read Meta‐analysis of Alzheimer’s disease clinical trial time savings results by Suzanne B. Hendrix, Kent Hendrix, Benjamin A Haaland, Patrick P O'Keefe, Newman Knowlton, Craig Mallinckrodt, Samuel P. Dickson (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11713539.txt.
Description
Alzheimer's trials traditionally judge a drug on three separate report cards — thinking tests, daily-function scales, and a global clinician rating — and a treatment can pass one while failing the others. Suzanne Hendrix and co-authors re-analyzed over a hundred studies of more than seventy treatments in 2025, judging each with a global statistical test that combines all three domains at once.
The combined lens changed verdicts. Some studies long written off as failures showed real positive signals; some celebrated ones looked clearly empty. A false positive is unlikely to strike all three domains together, the authors argue, so the combined test is the more honest referee. Grouping similar treatments across programs also exposed overlooked mechanisms and settled failures. They suggest composite judging might have spared the field some famous controversies.
Catalog record
| CREATOR | Suzanne B. Hendrix, Kent Hendrix, Benjamin A Haaland, Patrick P O'Keefe, Newman Knowlton, Craig Mallinckrodt, Samuel P. Dickson |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |